WO1998003643A2 - Animaux transgenic avec sequences app ou a4ct mutantes humaines - Google Patents
Animaux transgenic avec sequences app ou a4ct mutantes humaines Download PDFInfo
- Publication number
- WO1998003643A2 WO1998003643A2 PCT/EP1997/003960 EP9703960W WO9803643A2 WO 1998003643 A2 WO1998003643 A2 WO 1998003643A2 EP 9703960 W EP9703960 W EP 9703960W WO 9803643 A2 WO9803643 A2 WO 9803643A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- construct
- app
- a4ct
- construct according
- seq
- Prior art date
Links
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 19
- 241001465754 Metazoa Species 0.000 title abstract description 9
- 230000035772 mutation Effects 0.000 claims abstract description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 10
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 claims abstract description 6
- 102000046783 human APP Human genes 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 27
- 238000003780 insertion Methods 0.000 claims description 14
- 230000037431 insertion Effects 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 12
- 102220269180 rs186659284 Human genes 0.000 claims description 12
- 102220040502 rs587778349 Human genes 0.000 claims description 12
- 210000004556 brain Anatomy 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 230000014509 gene expression Effects 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 6
- 102220395130 c.128C>G Human genes 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 102220153369 rs147612968 Human genes 0.000 claims description 5
- 108091026890 Coding region Proteins 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 230000003542 behavioural effect Effects 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 claims description 2
- 102220552925 Fidgetin-like protein 1_V46P_mutation Human genes 0.000 claims description 2
- 102220597401 G0/G1 switch protein 2_V46A_mutation Human genes 0.000 claims description 2
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 claims description 2
- 101000828537 Homo sapiens Synaptic functional regulator FMR1 Proteins 0.000 claims description 2
- 101100231531 Mus musculus Hmgcr gene Proteins 0.000 claims description 2
- 101001018320 Mus musculus Myelin basic protein Proteins 0.000 claims description 2
- 101100298534 Mus musculus Prnp gene Proteins 0.000 claims description 2
- 101100260568 Mus musculus Thy1 gene Proteins 0.000 claims description 2
- 102000008763 Neurofilament Proteins Human genes 0.000 claims description 2
- 108010088373 Neurofilament Proteins Proteins 0.000 claims description 2
- 102000004316 Oxidoreductases Human genes 0.000 claims description 2
- 102220502428 Polyadenylate-binding protein 2_V46W_mutation Human genes 0.000 claims description 2
- 101001058233 Rattus norvegicus Gamma-enolase Proteins 0.000 claims description 2
- 101000821095 Rattus norvegicus Synapsin-1 Proteins 0.000 claims description 2
- 241000283984 Rodentia Species 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 239000006143 cell culture medium Substances 0.000 claims description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005516 coenzyme A Substances 0.000 claims description 2
- 229940093530 coenzyme a Drugs 0.000 claims description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 claims description 2
- 102000045409 human FMR1 Human genes 0.000 claims description 2
- 125000001165 hydrophobic group Chemical group 0.000 claims description 2
- 210000005044 neurofilament Anatomy 0.000 claims description 2
- 210000004248 oligodendroglia Anatomy 0.000 claims description 2
- 102200024635 rs132630289 Human genes 0.000 claims description 2
- 102220067614 rs141174358 Human genes 0.000 claims description 2
- 102220047655 rs587783134 Human genes 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101000766305 Mus musculus Serotransferrin Proteins 0.000 claims 1
- 102000004243 Tubulin Human genes 0.000 claims 1
- 108090000704 Tubulin Proteins 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 7
- 208000037259 Amyloid Plaque Diseases 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 24
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 24
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 24
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000004900 c-terminal fragment Anatomy 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- PJRSUKFWFKUDTH-JWDJOUOUSA-N (2s)-6-amino-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]propanoyl Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O PJRSUKFWFKUDTH-JWDJOUOUSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- NFNVDJGXRFEYTK-YUMQZZPRSA-N Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O NFNVDJGXRFEYTK-YUMQZZPRSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 108010021753 peptide-Gly-Leu-amide Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Definitions
- This invention relates to modified amyloid precursor proteins and their use in the production of transgenic animals.
- the main protein component of the amyloid plaques found in the brain of Alzheimer's disease (AD) patients is ⁇ A4, a 4 kDa peptide consisting of mainly forty and forty-two residues ( ⁇ A4 0 , ⁇ A4 2 ) being derived from the amyloid precursor protein (APP).
- APP amyloid precursor protein
- ⁇ -secretase APP can be cleaved at the N-terminus of ⁇ A4 generating a soluble APP and the C-terminal fragment A4CT (C99).
- This 99 residue long membrane protein A4CT (ref. 1) which is the direct precursor for ⁇ A4 contains the entire ⁇ A4 domain, the membrane domain and the cytoplasmic tail of APP.
- ⁇ -secretase Alternative processing of APP in a post-Golgi-compartment by a protease termed ⁇ -secretase leads to the cleavage of APP within the ⁇ A4 domain yielding secretory APP and the transmembrane fragment p3CT which is the direct precursor for p3.
- Both C-terminal fragments of APP, A4CT and p3CT are cleaved within the membrane domain by a ⁇ -cleavage activity, thereby releasing ⁇ A4 and p3 into the medium (refs. 2, 3).
- the site of ⁇ -cleavage is mainly the peptide bond Val(40)-Ile(41 )of A4CT and to a minor extent the bond Ala(42)- Thr(43).
- APP with the Familial AD linked mutations at Val 717 (based on APP770, Val 46 of A4CT) an increased ⁇ -cleavage occurs behind Val(42), thus producing larger amounts of ⁇ A4 1-42 (ref. 4).
- Transgenic mice expressing A4CT have been produced using the human APP promoter (ref. 5), the human thy- 1 promoter (ref. 6) and the JC viral early region promoter (ref. 7). Numerous promoters have been used in conjunction with the full length APP cDNA (ref. 12).
- transgenic mammals bearing APP derived DNA sequences are also described in WO93/14200 (TSI Corporation), WO91/19810 (California Biotechnology Inc), WO93/02189 (University of Calfornia), WO89/00689, WO92/06187 (The Upjohn Company), EP0451700 (Miles Inc.), WO92/13069 (Imperial College of Science Technology and Medicine) and WO89/06689 (McClean Hospital Corporation). Results obtained depend upon the source of the promoter and the protein coding sequence used.
- ⁇ A4,_, j peptide is the major subunit of amorphous and neuritic plaques in
- references herein to A4CT, ⁇ A4, J2 and ⁇ A4 1J0 include all N-terminal va ⁇ ants produced by alternative cleavage du ⁇ ng processing.
- a non-human transgenic mammal whose cells contain a construct comp ⁇ sing a human APP or A4CT DNA sequence encoding a mutation selected from: (i) T43A, T43S, T43G, T43V, T43L, T43I or T43F; and
- Mutation (I) is preferably selected from T43A and T43S
- Insertion (n) is preferably located between residues 42 and 53, more preferably between 46 and 53. In a preferred embodiment the insertion is located between T48 and L49.
- the residues for insertion (n) are preferably selected from F, I, G, Y, L, A, P, W, M, S, T, N and Q.
- the insertion (n) is preferably 2 to 6 residues long. In a preferred embodiment the insertion (n) is LV
- construct additionally encodes a mutation selected from-
- V46F V46I, V46G, V46Y, V46L, V46A.
- V46P V46W, V46M, V46S, V46T, V46N or V46Q.
- the additional mutation is V46F
- the construct further encodes the APP signal sequence
- APP residues 1 to 17 immediately upstream of the APP or A4CT DNA sequence.
- Hydrophobic residue inserts such as LeuGlu or Met are necessary for processing of A4CT to ⁇ A4 and should preferably be included between the signal peptide and A4CT coding regions and will remain attached to the processed A4CT.
- the invention also relates to mammalian cells expressing the construct and to the
- transgenic mammals of the invention may be carried out conventionally, for example as described in WO93/14200, WO91/19810, WO93/02189, WO89/00689, WO92/061 7, EP0451700, WO92/13069 and WO89/06689.
- the APP or A4CT coding DNA is obtained by probing a human cDNA library.
- Suitable promoters for use in the present invention include: Human APP (ref. 5); rat neuron specific enolase (neurons) (ref. 18); human ⁇ actin (ref. 19); human PDGF ⁇ (ref. 20); mouse Thy 1 (ref. 21); mouse P ⁇ on protein promoter (PrP) (ref. 14); rat synapsin 1 (brain) (ref. 22), human FMR1 (brain) (ref. 23); human neurofilament low (ref. 24), middle (brain) (ref. 25), NEX-1 (brain) (ref.
- mouseAPLP2 (brain) (ref. 27); rat alpha tubu n (ref. 28), mouse transfer ⁇ n (ref. 29), mouse HMGCR (3-hydroxy- 3-methyiglutaryl coenzyme A reductase, oligodendrocytes) (ref. 30) and mouse myelin basic protein (ref. 31).
- a tetracycline-inducible system may also be used, which has the advantage of regulating the gene expression (induction/repression) (refs. 33, 32).
- This system uses two constructs, a minimal promoter (PhCMV*-l ) fused to seven tetracychc operator sequences and the cDNA in question, and a trangene containing the tetracycline- controlled tran-activator protein (tTA) coding sequence under the control of a promoter, for example taken from the above list.
- tTA tetracycline- controlled tran-activator protein
- a preferred promoter is the mouse P ⁇ on protein promoter (ref. 14)
- the construct is prepared by conventional recombinant DNA techniques (ref. 10).
- the transgenic mammal is produced by conventional techniques (refs. 8, 15, 16, 17).
- the transgenic mammal is produced by introduction of the construct into an embryo, insertion of the embryo into a surrogate mother and allowing the embryo to develop to term.
- the construct is prepared for transfer to the host animal by cleavage of vector containing the construct and purification of the DNA (ref. 8)
- the transfer is carried out conventionally preferably using microinjection as described in detail in reference 8.
- the transgenic mammal is produced by introduction of the construct into embryonic stem cells by conventional methods such as calcium phosphate/DNA precipitation, direct inaction or electroporation (ref. 9) followed by injection of the transformed cells into blastocytes and insertion of the resulting embryo into a surrogate mother as described above
- Transgenic animals are identified by DNA analyis using Southern blot and PCR to detect founder animals
- the transgenic mammal is preferably a rodent such as rat or mouse, more preferably a mouse.
- Mammalian cells expressing the construct may be prepared by conventional methods.
- Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector.
- the vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc.
- the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the human genes.
- the culture conditions such as temperature, pH and the like will be apparent to the ordinarily skilled artisan.
- mammalian cell culture systems can be employed to express recombinant protein.
- mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell, 23.175 ( 1981 ), and other cell lines capable of expressing a compatible vector, for example, the SH-S Y5Y, CHO and HeLa cell lines.
- Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.
- the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as hygromycin or neomycin resistance for eukaryotic cell culture.
- the approp ⁇ ate DNA sequence may be inserted into the vector by a variety of procedures.
- the DNA sequence is inserted into an approp ⁇ ate restriction endonuciease s ⁇ te(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.
- the DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis.
- promoters include the CMV promoter, pCEP4 (Invitrogen) and other promoters known to control expression of genes in eukaryotic cells or their viruses and replicable and viable in the host
- Introduction of the construct into the host cell can be effected by calcium phosphate transfection, lipofectin-mediated transfection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986))
- the transgenic mammal or cells of the invention may be used to screen for drugs which inhibit deposit of ⁇ A4 by administe ⁇ ng test drug to the mammal or cell culture medium and observing changes in APP expression and processing, histopathology and/or behavioural changes.
- the invention extends to such method of screening
- SPA4CT C-terminal insertion ('CTI') ⁇ n the transmembrane domain (LV between T48 and L49) (SEQ ID NOs: 1 1 and 12) as well as a construct carrying the FAD mutation SPA4CT V46F wtSPA4CT consists of the 17 amino acid long signal peptide of APP followed by two additional amino acids of APP 695 (Leu and Glu) and then continuing with the ⁇ A4 sequence and the whole C-terminal domain and the mutagenesis was earned out in vector pSP65/SPA4CT (ref.
- SPA4CT T43F was carried out in pBS/SPA4CT rev
- pBS/SPA4CT rev was obtained by cloning the Kpnl/Nhe fragment of pCEP/SPA4CT (ref. 2) in the pBS/SPC99 vector (ref.
- constructs were inserted into pCEP vector (ref. 2) and were stably transfected into COS7 cells.
- G2-1 1 (monoclonal) against synthetic peptide ⁇ A4 35-42 for the immunoprecipitation of ⁇ A4 ⁇ -42
- 692 polyclonal rabbit serum against synthetic peptide ⁇ A4 1-40 for the immunoprecipitation of ⁇ A4.
- n-40 and n-42 stand for peptides with a defined C-termmus (ie residue 40 or 42 respectively of ⁇ A4) but allowing for possible N-terminal homogeneity.
- the full length ⁇ A4 forms produced by the particular constructs desc ⁇ bed herein contain Leu, Glu at positions -2, - 1.
- the stably transfected COS7 cells were metabohcally labeled for 10 min in methionine free MEM-medium containing 133 ⁇ G/ml 3S S-methion ⁇ ne.
- A4CT was immunoprecipitated with polyclonal antibody against A4CT (ref. 2), separated on a 10% T ⁇ s-T ⁇ cine gel and quantified by phospho ⁇ maging.
- the mutations near the C-terminus of ⁇ A4 are able to influence the ⁇ -cleavage site, whereas the overall amount of generated ⁇ A4 as well as the ratio of ⁇ A4/p3 remain unchanged.
- the single mutants ( I ), (2) and (3) have an increased ratio ⁇ A4 2 / ⁇ A4 1 40 relative to wt.
- the double mutants (4), (5) and (6) lead, respectively, to a 5.6-, 5.8 and 4.1 -fold increase in ⁇ A4 2 / ⁇ A4, 4n relative to wt.
- constructs which produce enhanced production of ⁇ A4 2 .relative to ⁇ A4, 4fl are useful for the generation of transgenic mice developing amyloid plaques.
- construct SPA4CT T43A+V46F driven by the mouse Prion protein promoter (ref. 14) is used to transform a mouse by the following procedures:
- the construct is prepared and purified. Female mice are induced to superovulate and embryos are recovered. DNA is microinjected into the pronucleus of embryos.
- Embryos are transferred into pseudopregnant mice (female mice previously paired with vasectomised males).
- mice Embryos are developed and mice are born. Founder mice are identified by Southern blot and PCR and bred on.
- mice are as follows: Donor mice (embryos for pronucleus injection): B6D2F2 Acceptor mice: NMRI Mice for further breeding: C57BL6
- transgenic mice described above may be used to screen for potential activity of test drugs in the treatment of Alzheimer's disease.
- APP expression and processing may be examined using detection of mRNA by
- Histopathological observations may be made using immunohistological techniques to permit identification of amyloid plaques and in situ hybridisation using labelled probes to target mRNA.
- Observation of behavioural changes may employ conventional tests used to assess learning and memory deficits.
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Produits de recombinaison qui comportent une séquence d'ADN APP ou A4CT codant des mutations qui entraînent un taux plus élevé de βA41-42/βA41-40 que le type sauvage et utilisation desdits produits dans la production d'animaux transgéniques développant des plaques amyloïdes, destinés à servir de modèles pour la maladie d'Alzheimer.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9615351.5A GB9615351D0 (en) | 1996-07-22 | 1996-07-22 | Compounds |
GB9615351.5 | 1996-07-22 | ||
GBGB9618804.0A GB9618804D0 (en) | 1996-09-09 | 1996-09-09 | Compounds |
GB9618804.0 | 1996-09-09 | ||
GBGB9709239.9A GB9709239D0 (en) | 1997-05-08 | 1997-05-08 | APP transgenic model |
GB9709239.9 | 1997-05-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998003643A2 true WO1998003643A2 (fr) | 1998-01-29 |
WO1998003643A3 WO1998003643A3 (fr) | 1998-04-30 |
Family
ID=27268398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/003960 WO1998003643A2 (fr) | 1996-07-22 | 1997-07-17 | Animaux transgenic avec sequences app ou a4ct mutantes humaines |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1998003643A2 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998058060A1 (fr) * | 1997-06-18 | 1998-12-23 | Smithkline Beecham Pharma Gmbh | Sequences app ou a4ct humaines codant la mutation 145f |
GB2380196A (en) * | 2001-08-21 | 2003-04-02 | Smithkline Beecham Plc | Transgenic animals with mutant human amyloid precursor protein sequences |
WO2004026331A1 (fr) * | 2002-09-17 | 2004-04-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Peptides inhibant les activites de clivage specifiques des presenilines |
US6815175B2 (en) | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
WO2006134342A3 (fr) * | 2005-06-13 | 2007-05-18 | Merck Sharp & Dohme | Proteines |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07506720A (ja) * | 1992-01-07 | 1995-07-27 | アテナ ニューロサイエンシーズ, インコーポレイテッド | アルツハイマー病のトランスジェニック動物モデル |
-
1997
- 1997-07-17 WO PCT/EP1997/003960 patent/WO1998003643A2/fr active Application Filing
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998058060A1 (fr) * | 1997-06-18 | 1998-12-23 | Smithkline Beecham Pharma Gmbh | Sequences app ou a4ct humaines codant la mutation 145f |
US6815175B2 (en) | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
GB2380196A (en) * | 2001-08-21 | 2003-04-02 | Smithkline Beecham Plc | Transgenic animals with mutant human amyloid precursor protein sequences |
WO2004026331A1 (fr) * | 2002-09-17 | 2004-04-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Peptides inhibant les activites de clivage specifiques des presenilines |
WO2006134342A3 (fr) * | 2005-06-13 | 2007-05-18 | Merck Sharp & Dohme | Proteines |
Also Published As
Publication number | Publication date |
---|---|
WO1998003643A3 (fr) | 1998-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7186881B2 (en) | Testing compounds for effects on synaptophysin in transgenic mice expressing an Alzheimer's disease FAD DNA sequence | |
CA2127450C (fr) | Modeles d'animaux transgeniques pour la maladie d'alzheimer | |
AU732508B2 (en) | Nucleic acids and proteins related to Alzheimer's disease, and uses therefor | |
US7309812B2 (en) | Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses | |
JPH09507746A (ja) | Swedish変異を有するAPP対立遺伝子を含有するトランスジェニック動物 | |
JPH09508196A (ja) | β−アミロイド・ペプチド生産インヒビターについてのスクリーニング方法 | |
JP2001517065A (ja) | トランスジェニック動物モデルを用いてアルツハイマー病治療薬を同定する方法 | |
US6670195B1 (en) | Mutant genes in Familial British Dementia and Familial Danish Dementia | |
US20020016978A1 (en) | Transgenic animal expressing non-native wild-type and familial alzheimer's disease mutant presenilin 1 protein on native presenilin 1 null background | |
EP0833901A1 (fr) | Procede pour identifier une therapeutique de la maladie d'alzheimer a l'aide de modeles animaux transgeniques | |
EP1027433B1 (fr) | Sequences app ou a4ct humaines codant la mutation 145f | |
WO1998003643A2 (fr) | Animaux transgenic avec sequences app ou a4ct mutantes humaines | |
US6734336B1 (en) | Gene-targeted non-human mammal with human fad presenilin mutation and generational offspring | |
JP5046413B2 (ja) | ヒトfadプレセニリン突然変異をもつ標的遺伝子組換え非ヒト哺乳動物および生殖による子孫 | |
US20050034182A1 (en) | Mouse showing neurofibril change due to senile dementia | |
CA2257304C (fr) | Animaux transgeniques de perlecane et procedes d'identification de composes pour le traitement des amyloidoses | |
DE60223205T2 (de) | Transgenes Tiermodell für Alzheimer-Erkrankung | |
EP1893641A2 (fr) | Mutants de l'app humaine et leur utilisation pour la production d'animaux transgeniques | |
WO1994024266A1 (fr) | Modeles animaux transgeniques pour la maladie d'alzheimer | |
Wadsworth et al. | Transgenic mouse expressing APP 770 | |
GB2380196A (en) | Transgenic animals with mutant human amyloid precursor protein sequences |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97535651 Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1997535651 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |